IN2014KN00943A - - Google Patents
Info
- Publication number
- IN2014KN00943A IN2014KN00943A IN943KON2014A IN2014KN00943A IN 2014KN00943 A IN2014KN00943 A IN 2014KN00943A IN 943KON2014 A IN943KON2014 A IN 943KON2014A IN 2014KN00943 A IN2014KN00943 A IN 2014KN00943A
- Authority
- IN
- India
- Prior art keywords
- compounds
- kinases
- variables
- study
- pharmaceutically acceptable
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 9
- 238000000034 method Methods 0.000 abstract 3
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 238000010835 comparative analysis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 230000031146 intracellular signal transduction Effects 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161541861P | 2011-09-30 | 2011-09-30 | |
| US201161554174P | 2011-11-01 | 2011-11-01 | |
| US201261620698P | 2012-04-05 | 2012-04-05 | |
| PCT/US2012/058121 WO2013049722A1 (fr) | 2011-09-30 | 2012-09-28 | Composés utiles comme inhibiteurs de kinase atr |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014KN00943A true IN2014KN00943A (fr) | 2015-08-21 |
Family
ID=47019162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN943KON2014 IN2014KN00943A (fr) | 2011-09-30 | 2012-09-28 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8846686B2 (fr) |
| EP (1) | EP2751099B1 (fr) |
| JP (1) | JP2014528419A (fr) |
| KR (1) | KR20140084112A (fr) |
| CN (1) | CN103958507A (fr) |
| AR (1) | AR088091A1 (fr) |
| AU (1) | AU2012315611A1 (fr) |
| CA (1) | CA2850564A1 (fr) |
| IL (1) | IL231814A0 (fr) |
| IN (1) | IN2014KN00943A (fr) |
| MX (1) | MX2014003796A (fr) |
| TW (1) | TW201332999A (fr) |
| WO (1) | WO2013049722A1 (fr) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2011006503A (es) * | 2008-12-19 | 2011-09-06 | Vertex Pharma | Derivados de pirazina utiles como inhibidores de la cinasa de atr. |
| EP2569286B1 (fr) | 2010-05-12 | 2014-08-20 | Vertex Pharmaceuticals Inc. | Composés utilisables en tant qu'inhibiteurs de la kinase atr |
| JP2013526540A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| EP2569289A1 (fr) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Pyrazines utiles en tant qu'inhibiteurs de la kinase atr |
| EP2568984A1 (fr) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Composés utiles en tant qu'inhibiteurs de l'atr kinase |
| NZ603478A (en) | 2010-05-12 | 2014-09-26 | Vertex Pharma | 2 -aminopyridine derivatives useful as inhibitors of atr kinase |
| EP2569313A1 (fr) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Composés utiles comme inhibiteurs de la kinase atr |
| CA2803802A1 (fr) | 2010-06-23 | 2011-12-29 | Vertex Pharmaceuticals Incorporated | Derives de pyrrolo-pyrazine utiles en tant qu'inhibiteurs de l'atr kinase |
| CN103562204A (zh) | 2011-04-05 | 2014-02-05 | 沃泰克斯药物股份有限公司 | 可用作tra激酶的抑制剂的氨基吡嗪化合物 |
| JP2014522818A (ja) | 2011-06-22 | 2014-09-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| EP2723745A1 (fr) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Composés utiles comme inhibiteurs de la kinase atr |
| US9309250B2 (en) | 2011-06-22 | 2016-04-12 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors |
| ES2940121T3 (es) | 2011-09-30 | 2023-05-03 | Vertex Pharma | Tratamiento de cáncer de pulmón de células no pequeñas con inhibidores de ATR |
| KR102184246B1 (ko) | 2011-09-30 | 2020-12-01 | 버텍스 파마슈티칼스 인코포레이티드 | Ａｔｒ 키나제의 억제제로서 유용한 화합물의 제조 방법 |
| JP2014528419A (ja) | 2011-09-30 | 2014-10-27 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| WO2013049719A1 (fr) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Composés utiles en tant qu'inhibiteurs de kinase atr |
| WO2013049720A1 (fr) * | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Composés utiles en tant qu'inhibiteurs de kinase atr |
| WO2013071090A1 (fr) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Composés utiles en tant qu'inhibiteurs de la kinase atr |
| EP2776421A1 (fr) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Composés utiles comme inhibiteurs de kinase atr |
| EP2776429A1 (fr) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Composés utiles comme inhibiteurs de kinase atr |
| EP2776420A1 (fr) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Composés de pyrazine utiles comme inhibiteurs de kinase atr |
| JP2015502925A (ja) | 2011-11-09 | 2015-01-29 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用なピラジン化合物 |
| DK2833973T3 (en) | 2012-04-05 | 2018-01-02 | Vertex Pharma | Compounds useful as ATR kinase inhibitors and combination therapies thereof |
| WO2014055756A1 (fr) | 2012-10-04 | 2014-04-10 | Vertex Pharmaceuticals Incorporated | Procédé pour la mesure d'augmentations de lésions d'adn à médiation par l'inhibition d'atr |
| EP2909202A1 (fr) * | 2012-10-16 | 2015-08-26 | Vertex Pharmaceuticals Incorporated | Composés utiles en tant qu'inhibiteurs de la kinase atr |
| HRP20180859T1 (hr) | 2012-12-07 | 2018-07-13 | Vertex Pharmaceuticals Incorporated | 2-amino-6-fluoro-n-(5-fluoro-4-(4-(4-(oksetan-3-il)piperazin-1-karbonil)piperidin-1-il)piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamid kao inhibitor atr kinaze |
| JP2016512815A (ja) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体 |
| HUE046727T2 (hu) | 2013-12-06 | 2020-03-30 | Vertex Pharma | Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai |
| KR102575125B1 (ko) | 2014-06-05 | 2023-09-07 | 버텍스 파마슈티칼스 인코포레이티드 | Atr 키나제의 저해제로서 유용한 2-아미노-6-플루오로-n-[5-플루오로-피리딘-3-일]-피라졸로[1,5-a]피리미딘-3-카복스아미드 화합물의 방사성표지된 유도체, 상기 화합물의 제조 및 이의 다양한 고체 형태 |
| CA2950780C (fr) | 2014-06-17 | 2023-05-16 | Vertex Pharmaceuticals Incorporated | Methode de traitement anticancereux utilisant une association d'inhibiteurs de chk1 et d'atr |
| TWI700283B (zh) | 2014-08-04 | 2020-08-01 | 德商拜耳製藥公司 | ２-(嗎啉-４-基)-１,７-萘啶 |
| CN105471583B (zh) * | 2014-09-11 | 2019-01-29 | 比亚迪股份有限公司 | 车载电器的电子认证方法和电子认证系统 |
| JP7187308B2 (ja) | 2015-09-30 | 2022-12-12 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｄｎａ損傷剤とａｔｒ阻害剤との組み合わせを使用する、がんを処置するための方法 |
| IL260487B2 (en) * | 2016-01-11 | 2024-11-01 | Merrimack Pharmaceuticals Inc | Inhibition of ataxia capillary dilation and related protein- (ATR) RAD3 |
| FR3058062A1 (fr) * | 2016-10-27 | 2018-05-04 | Selexel | Nouvelle utilisation d'un oligonucleotide double brin |
| WO2018153972A1 (fr) | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Combinaison d'inhibiteurs de kinase atr et d'anti-androgènes |
| TW201840319A (zh) | 2017-02-24 | 2018-11-16 | 德商拜耳廠股份有限公司 | Atr激酶抑制劑與鐳-223鹽之組合 |
| JOP20190197A1 (ar) | 2017-02-24 | 2019-08-22 | Bayer Pharma AG | مثبط كيناز ايه تي آر للاستخدام في طريقة لعلاج مرض فرط التكاثر |
| WO2018206547A1 (fr) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combinaison d'inhibiteurs de bub1 et d'atr |
| US11690911B2 (en) | 2017-08-04 | 2023-07-04 | Bayer Aktiengesellschaft | Combination of ATR kinase inhibitors and PD-1/PD-L1 inhibitors |
| EP3461480A1 (fr) | 2017-09-27 | 2019-04-03 | Onxeo | Combinaison d'inhibiteurs de point de contrôle du cycle cellulaire de réponse à un dommage à l'adn et de belinostat pour traiter le cancer |
| CA3084863A1 (fr) | 2017-12-08 | 2019-06-13 | Bayer Aktiengesellschaft | Marqueurs predictifs pour inhibiteurs d'atr kinase |
| CN109507429A (zh) * | 2018-02-14 | 2019-03-22 | 复旦大学 | 基于CRISPR/cas9和过氧化物酶APEX2系统识别分析特异性位点相互作用蛋白的方法 |
| CA3114024A1 (fr) | 2018-09-26 | 2020-04-02 | Merck Patent Gmbh | Combinaison d'un antagoniste de pd-1, d'un inhibiteur d'atr et d'un agent de platination pour le traitement du cancer |
| EP3866785A1 (fr) | 2018-10-15 | 2021-08-25 | Merck Patent GmbH | Polythérapie utilisant des agents d'alkylation d'adn et des inhibiteurs d'atr |
| CA3116230A1 (fr) | 2018-10-16 | 2020-04-23 | Bayer Aktiengesellschaft | Combinaison d'inhibiteurs de kinase atr avec des composes de 2,3-dihydro-imidazo[1,2-c]quinazoline |
| CN112899321B (zh) * | 2019-11-19 | 2024-12-24 | 上海天慈国际药业有限公司 | 一种劳拉替尼关键中间体制备方法 |
| CN112694497A (zh) * | 2020-12-25 | 2021-04-23 | 蚌埠中实化学技术有限公司 | 一种4-异丙基磺酰基苯硼酸的制备方法 |
| WO2022237875A1 (fr) * | 2021-05-12 | 2022-11-17 | 正大天晴药业集团股份有限公司 | Composé inhibiteur de l'atr contenant une sulfoximine |
| TW202321230A (zh) * | 2021-08-13 | 2023-06-01 | 大陸商蘇州愛科百發生物醫藥技術有限公司 | 用作ａｔｒ激酶抑制劑的化合物 |
| CN116444496B (zh) * | 2023-06-16 | 2023-11-24 | 药康众拓(北京)医药科技有限公司 | 一种嘧啶联氘代吡唑类化合物及其应用 |
Family Cites Families (128)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4309430A (en) | 1980-06-27 | 1982-01-05 | Merck & Co., Inc. | Pyrazinyl-1,2,4-oxadiazole-5-ones, for treatment of edema, and processes for preparing same |
| US5329012A (en) | 1987-10-29 | 1994-07-12 | The Research Foundation Of State University Of New York | Bis(acyloxmethyl)imidazole compounds |
| JP2597917B2 (ja) | 1990-04-26 | 1997-04-09 | 富士写真フイルム株式会社 | 新規な色素形成カプラー及びそれを用いたハロゲン化銀カラー写真感光材料 |
| WO1997043267A1 (fr) | 1996-05-11 | 1997-11-20 | Kings College London | Pyrazines |
| JP2002241379A (ja) | 1997-03-21 | 2002-08-28 | Dainippon Pharmaceut Co Ltd | ３−オキサジアゾリルキノキサリン誘導体 |
| KR20010071936A (ko) | 1998-07-16 | 2001-07-31 | 시오노 요시히코 | 항종양 활성을 갖는 피리미딘 유도체 |
| US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| AU782858B2 (en) | 1999-12-17 | 2005-09-01 | Novartis Vaccines And Diagnostics, Inc. | Pyrazine based inhibitors of glycogen synthase kinase 3 |
| US6849660B1 (en) | 2000-08-01 | 2005-02-01 | Isis Pharmaceuticals, Inc. | Antimicrobial biaryl compounds |
| EP1217000A1 (fr) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibiteurs du factor Xa et factor VIIa |
| WO2002089738A2 (fr) | 2001-05-08 | 2002-11-14 | Yale University | Composes proteomimetiques et procedes correspondants |
| SE0102438D0 (sv) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| SE0102439D0 (sv) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| US6992087B2 (en) | 2001-11-21 | 2006-01-31 | Pfizer Inc | Substituted aryl 1,4-pyrazine derivatives |
| AU2002343557A1 (en) | 2001-11-21 | 2003-06-10 | Pharmacia And Upjohn Company | Substituted aryl 1,4-pyrazine derivatives |
| KR20040084896A (ko) | 2002-02-06 | 2004-10-06 | 버텍스 파마슈티칼스 인코포레이티드 | Ｇｓｋ-3의 억제제로서 유용한 헤테로아릴 화합물 |
| ATE395343T1 (de) | 2002-03-13 | 2008-05-15 | Janssen Pharmaceutica Nv | Sulfonylderivate als histone-deacetylase- inhibitoren |
| GB0206860D0 (en) | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
| TWI319387B (en) | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
| GB0209715D0 (en) | 2002-04-27 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| CA2484209C (fr) | 2002-05-03 | 2013-06-11 | Exelixis, Inc. | Modulateurs de proteine kinase et procedes d'utilisation |
| US7704995B2 (en) | 2002-05-03 | 2010-04-27 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| CN1656079A (zh) | 2002-05-31 | 2005-08-17 | 卫材株式会社 | 吡唑化合物和含有该化合物的药物组合物 |
| WO2004000318A2 (fr) | 2002-06-21 | 2003-12-31 | Cellular Genomics, Inc. | Utilisation de certains monocycles a substitution amino en tant que modulateurs de l'activite des kinases |
| AU2003282679A1 (en) | 2002-10-04 | 2004-05-04 | Arena Pharmaceuticals, Inc. | Hydroxypyrazoles for use against metabolic-related disorders |
| SE0203754D0 (sv) | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
| SE0203752D0 (sv) | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
| EP1606267B1 (fr) | 2003-03-11 | 2008-07-30 | Pfizer Products Inc. | Composes de pyrazine utiles comme inhibiteurs du facteur de croissance transformant (tgf) |
| EP1606266A4 (fr) | 2003-03-21 | 2008-06-25 | Smithkline Beecham Corp | Composes chimiques |
| CA2519677A1 (fr) | 2003-03-24 | 2004-10-07 | Merck & Co., Inc. | Heterocycles a 6 elements a substitution biaryle en tant que bloqueurs des canaux sodiques |
| GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
| CN1788008A (zh) | 2003-05-15 | 2006-06-14 | 麦克公司 | 作为s1p受体激动剂的3－(2－氨基－1－氮杂环基)－5－芳基－1,2,4－噁二唑 |
| TWI339206B (en) | 2003-09-04 | 2011-03-21 | Vertex Pharma | Compositions useful as inhibitors of protein kinases |
| US7807696B2 (en) | 2003-10-07 | 2010-10-05 | The Feinstein Institute For Medical Research | Isoxazole and isothiazole compounds useful in the treatment of inflammation |
| AU2005215379A1 (en) | 2004-02-12 | 2005-09-01 | Merck & Co., Inc. | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 |
| JP2008502687A (ja) | 2004-06-14 | 2008-01-31 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
| US7452993B2 (en) | 2004-07-27 | 2008-11-18 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
| US7626021B2 (en) | 2004-07-27 | 2009-12-01 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
| EP1828144A2 (fr) | 2004-11-12 | 2007-09-05 | OSI Pharmaceuticals, Inc. | Antagonistes de l'integrine utiles en tant qu'agents anticancereux |
| MX2007006103A (es) | 2004-11-22 | 2007-07-20 | Vertex Pharma | Pirrolopirazinas y pirazolopirazinas de utilidad como inhibidores de proteinquinasas. |
| GB0428235D0 (en) | 2004-12-23 | 2005-01-26 | Glaxo Group Ltd | Novel compounds |
| JP2008525453A (ja) | 2004-12-27 | 2008-07-17 | アルコン，インコーポレイティド | 緑内障と、ｒｈｏキナーゼを媒介とした他の疾患および症状を治療するためのアミノピラジン・アナログ |
| GB0500492D0 (en) | 2005-01-11 | 2005-02-16 | Cyclacel Ltd | Compound |
| US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| PE20061093A1 (es) | 2005-02-16 | 2006-11-10 | Schering Corp | Piperazinas sustituidas con heterociclos con actividad antagonista de cxcr3 |
| CA2605738C (fr) | 2005-04-25 | 2013-10-01 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Nouveaux aza-heterocycles constituant des inhibiteurs de kinases |
| WO2007015632A1 (fr) | 2005-08-04 | 2007-02-08 | Cgk Co., Ltd. | Inhibiteur d’atm et d’atr |
| TW200736260A (en) | 2005-11-10 | 2007-10-01 | Smithkline Beecham Corp | Inhibitors of Akt activity |
| ATE452635T1 (de) | 2005-12-01 | 2010-01-15 | Hoffmann La Roche | Heteroaryl-substituierte piperidin-derivate als l-cpt1-hemmer |
| WO2007066805A1 (fr) | 2005-12-09 | 2007-06-14 | Meiji Seika Kaisha, Ltd. | Derive de lincomycine et agent antibacterien le contenant en tant qu’ingredient actif |
| ZA200804497B (en) | 2005-12-22 | 2009-10-28 | Alcon Res Ltd | (Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating rho kinase-mediated diseases and conditions |
| ITMI20060311A1 (it) | 2006-02-21 | 2007-08-22 | Btsr Int Spa | Dispositivo perfezionato di alimentazione di filo o filatio ad una macchina tessile e metodo per attuare tale alimentazione |
| GB0603684D0 (en) | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
| WO2007096764A2 (fr) | 2006-02-27 | 2007-08-30 | Glenmark Pharmaceuticals S.A. | Dérivés d'hétéroaryles bicycliques en tant que modulateurs des récepteurs cannabinoïdes |
| TW200800203A (en) | 2006-03-08 | 2008-01-01 | Astrazeneca Ab | New use |
| AU2007231577B2 (en) | 2006-03-22 | 2012-07-19 | Vertex Pharmaceuticals Incorporated | c-MET protein kinase inhibitors for the treatment of proliferative disorders |
| US7700601B2 (en) | 2006-03-31 | 2010-04-20 | Schering Corporation | Substituted indazoles of formula 1.0 that are kinase inhibitors |
| EP2044051B1 (fr) | 2006-06-22 | 2010-01-27 | BIOVITRUM AB (publ) | Dérivés de pyridine et de pyrazine utilisés en tant qu'inhibiteurs de la kinase mnk |
| AU2007261397A1 (en) | 2006-06-22 | 2007-12-27 | Mallinckrodt Llc | Pyrazine derivatives with extended conjugation and uses thereof |
| BRPI0717564A2 (pt) | 2006-09-29 | 2013-10-22 | Novartis Ag | Pirazolopirimidinas como inibidores de pi3k lipídeo cinase |
| GB0619342D0 (en) | 2006-09-30 | 2006-11-08 | Vernalis R&D Ltd | New chemical compounds |
| EP2450350A1 (fr) | 2006-10-04 | 2012-05-09 | F. Hoffmann-La Roche AG | Dérivés de 3-pyridinecarboxamide et de 2-pyrazinecarboxamide en tant qu'agents augmentant le cholestérol HDL |
| US8148361B2 (en) | 2006-11-10 | 2012-04-03 | Bristol-Myers Squibb Company | Kinase inhibitors |
| KR20090088962A (ko) | 2006-12-15 | 2009-08-20 | 바이엘 쉐링 파마 악티엔게젤샤프트 | ３-ｈ-피라졸로피리딘 및 그의 염, 이를 포함하는 제약 조성물, 이의 제조 방법 및 이의 용도 |
| US7687522B2 (en) | 2006-12-20 | 2010-03-30 | Amgen Inc. | Substituted pyridines and pyrimidines and their use in treatment of cancer |
| GB0625659D0 (en) | 2006-12-21 | 2007-01-31 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| PE20121126A1 (es) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
| EP2114898A2 (fr) | 2007-02-16 | 2009-11-11 | Amgen Inc. | Cétones d'hétérocyclyle contenant de l'azote et procédés d'utilisation |
| CA2679659C (fr) | 2007-03-01 | 2016-01-19 | Novartis Ag | Inhibiteurs de pim kinase et procedes de leur utilisation |
| EP2181100A2 (fr) | 2007-04-10 | 2010-05-05 | Bayer CropScience AG | Dérivés d'arzlisoxayoline insecticides |
| WO2008141065A1 (fr) | 2007-05-10 | 2008-11-20 | Smithkline Beecham Corporation | Dérivés de quinoxaline comme inhibiteurs de p13 kinase |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| UY31137A1 (es) | 2007-06-14 | 2009-01-05 | Smithkline Beecham Corp | Derivados de quinazolina como inhibidores de la pi3 quinasa |
| WO2008156174A1 (fr) | 2007-06-21 | 2008-12-24 | Taisho Pharmaceutical Co., Ltd. | Composé de pyrazinamide |
| US20090005381A1 (en) | 2007-06-26 | 2009-01-01 | Philip Manton Brown | Methods of treating serotonin-mediated diseases and disorders |
| GB0713259D0 (en) | 2007-07-09 | 2007-08-15 | Astrazeneca Ab | Pyrazine derivatives 954 |
| CA2693967A1 (fr) | 2007-07-19 | 2009-01-29 | Schering Corporation | Composes heterocycliques d'amide en tant qu'inhibiteurs de proteine kinase |
| BRPI0813426A2 (pt) | 2007-07-19 | 2014-12-23 | Lundbeck & Co As H | Composto, composição farmacêutica, métodos para modular a atividade de um receptor p2x7, para tratar uma condição, para inibir a morte de células gangliônicas retinais, para promover perda de peso,e para determinar a presença ou ausência de receptor p2x7 em uma amostra, preparação farmacêutica acondicionada, uso de composto ou sal ou hidrato do mesmo. |
| AU2008281543A1 (en) | 2007-08-01 | 2009-02-05 | Pfizer Inc. | Pyrazole compounds and their use as Raf inhibitors |
| WO2009024825A1 (fr) | 2007-08-21 | 2009-02-26 | Astrazeneca Ab | Dérivés de 2-pyrazinylbenzimidazole en tant qu'inhibiteurs des récepteurs tyrosine kinase |
| US8415358B2 (en) | 2007-09-17 | 2013-04-09 | Neurosearch A/S | Pyrazine derivatives and their use as potassium channel modulators |
| AU2008315746A1 (en) | 2007-10-25 | 2009-04-30 | Astrazeneca Ab | Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders |
| JP5529049B2 (ja) | 2008-02-25 | 2014-06-25 | エフ．ホフマン−ラ ロシュ アーゲー | ピロロピラジンキナーゼ阻害剤 |
| CA2716223A1 (fr) | 2008-02-25 | 2009-09-03 | F. Hoffmann-La Roche Ag | Inhibiteurs de kinase pyrrolopyrazine |
| ATE522535T1 (de) | 2008-02-25 | 2011-09-15 | Hoffmann La Roche | Pyrrolotriazin-kinasehemmer |
| CA2713718A1 (fr) | 2008-02-25 | 2009-09-03 | F. Hoffmann-La Roche Ag | Inhibiteurs de kinase pyrrolopyrazine |
| TW200940537A (en) | 2008-02-26 | 2009-10-01 | Astrazeneca Ab | Heterocyclic urea derivatives and methods of use thereof |
| WO2009152087A1 (fr) | 2008-06-10 | 2009-12-17 | Plexxikon, Inc. | Composés hétéroaryles bicycliques et procédés destinés à la modulation de kinases, et des indications pour celle-ci |
| GB0814364D0 (en) | 2008-08-05 | 2008-09-10 | Eisai London Res Lab Ltd | Diazaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase |
| JP2012506381A (ja) | 2008-10-21 | 2012-03-15 | バーテックス ファーマシューティカルズ インコーポレイテッド | ｃ−ＭＥＴタンパク質キナーゼ阻害剤 |
| AU2009313198B2 (en) | 2008-11-10 | 2016-03-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| CN102264743B (zh) | 2008-11-25 | 2015-02-11 | 罗彻斯特大学 | Mlk抑制剂及其使用方法 |
| ES2464458T3 (es) | 2008-12-05 | 2014-06-02 | F. Hoffmann-La Roche Ag | Pirrolopirazinil-ureas como inhibidores de quinasas |
| MX2011006503A (es) | 2008-12-19 | 2011-09-06 | Vertex Pharma | Derivados de pirazina utiles como inhibidores de la cinasa de atr. |
| CN102264737A (zh) | 2008-12-23 | 2011-11-30 | 雅培制药有限公司 | 抗病毒化合物 |
| CN102388043A (zh) | 2009-02-11 | 2012-03-21 | 桑诺维恩药品公司 | 组胺h3反相激动剂和拮抗剂及其使用方法 |
| WO2010111653A2 (fr) | 2009-03-27 | 2010-09-30 | The Uab Research Foundation | Modulation de la traduction à médiation par les séquences ires |
| JP2012533551A (ja) | 2009-07-15 | 2012-12-27 | アボット・ラボラトリーズ | ピロロピラジン系キナーゼ阻害薬 |
| US8518945B2 (en) | 2010-03-22 | 2013-08-27 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
| EP2556060A1 (fr) | 2010-04-08 | 2013-02-13 | Ah Usa 42 Llc | Dérivés de 3,5-diphényl-isoxazoline substitués comme insecticides et acaricides |
| EP2558866B1 (fr) | 2010-04-15 | 2016-08-17 | Tracon Pharmaceuticals, Inc. | Potentialisation de l'activité anticancéreuse par polythérapie avec des inhibiteurs de la voie ber |
| JP2013526540A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| EP2569313A1 (fr) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Composés utiles comme inhibiteurs de la kinase atr |
| EP2568984A1 (fr) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Composés utiles en tant qu'inhibiteurs de l'atr kinase |
| EP2569289A1 (fr) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Pyrazines utiles en tant qu'inhibiteurs de la kinase atr |
| NZ603478A (en) | 2010-05-12 | 2014-09-26 | Vertex Pharma | 2 -aminopyridine derivatives useful as inhibitors of atr kinase |
| EP2569286B1 (fr) | 2010-05-12 | 2014-08-20 | Vertex Pharmaceuticals Inc. | Composés utilisables en tant qu'inhibiteurs de la kinase atr |
| CA2798970A1 (fr) | 2010-05-20 | 2011-11-24 | F. Hoffmann-La Roche Ag | Derives de pyrrolopyrazine comme inhibiteurs de syk et jak |
| KR20130083386A (ko) | 2010-05-20 | 2013-07-22 | 에프. 호프만-라 로슈 아게 | 피롤로[2,3-ｂ]피라진-7-카복스아마이드 유도체 및 ＪＡＫ 및 ＳＹＫ 억제제로서의 그의 용도 |
| CA2803802A1 (fr) | 2010-06-23 | 2011-12-29 | Vertex Pharmaceuticals Incorporated | Derives de pyrrolo-pyrazine utiles en tant qu'inhibiteurs de l'atr kinase |
| CN102311396B (zh) | 2010-07-05 | 2015-01-07 | 暨南大学 | 一种吡嗪类衍生物和其制备方法及在制药中的应用 |
| EP2407478A1 (fr) | 2010-07-14 | 2012-01-18 | GENETADI Biotech, S.L. | Nouveaux cyclotetrapeptides ayant des propriétés pro-angiogenèse |
| CN103562204A (zh) | 2011-04-05 | 2014-02-05 | 沃泰克斯药物股份有限公司 | 可用作tra激酶的抑制剂的氨基吡嗪化合物 |
| CA2836417A1 (fr) | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Derives aza-indoliques utilises comme inhibiteurs de tyrosine kinases |
| EP2723745A1 (fr) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Composés utiles comme inhibiteurs de la kinase atr |
| JP2014522818A (ja) | 2011-06-22 | 2014-09-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| US9309250B2 (en) | 2011-06-22 | 2016-04-12 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors |
| KR102184246B1 (ko) | 2011-09-30 | 2020-12-01 | 버텍스 파마슈티칼스 인코포레이티드 | Ａｔｒ 키나제의 억제제로서 유용한 화합물의 제조 방법 |
| WO2013049720A1 (fr) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Composés utiles en tant qu'inhibiteurs de kinase atr |
| WO2013049719A1 (fr) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Composés utiles en tant qu'inhibiteurs de kinase atr |
| JP2014528419A (ja) | 2011-09-30 | 2014-10-27 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| ES2940121T3 (es) | 2011-09-30 | 2023-05-03 | Vertex Pharma | Tratamiento de cáncer de pulmón de células no pequeñas con inhibidores de ATR |
| JP2015502925A (ja) | 2011-11-09 | 2015-01-29 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用なピラジン化合物 |
| EP2776421A1 (fr) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Composés utiles comme inhibiteurs de kinase atr |
| EP2776429A1 (fr) * | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Composés utiles comme inhibiteurs de kinase atr |
| EP2776420A1 (fr) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Composés de pyrazine utiles comme inhibiteurs de kinase atr |
| WO2013071090A1 (fr) * | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Composés utiles en tant qu'inhibiteurs de la kinase atr |
-
2012
- 2012-09-28 JP JP2014533440A patent/JP2014528419A/ja active Pending
- 2012-09-28 IN IN943KON2014 patent/IN2014KN00943A/en unknown
- 2012-09-28 CN CN201280057953.0A patent/CN103958507A/zh active Pending
- 2012-09-28 AU AU2012315611A patent/AU2012315611A1/en not_active Abandoned
- 2012-09-28 MX MX2014003796A patent/MX2014003796A/es not_active Application Discontinuation
- 2012-09-28 CA CA2850564A patent/CA2850564A1/fr not_active Abandoned
- 2012-09-28 US US13/631,732 patent/US8846686B2/en not_active Expired - Fee Related
- 2012-09-28 KR KR1020147011922A patent/KR20140084112A/ko not_active Withdrawn
- 2012-09-28 EP EP12772855.8A patent/EP2751099B1/fr not_active Not-in-force
- 2012-09-28 WO PCT/US2012/058121 patent/WO2013049722A1/fr not_active Ceased
- 2012-10-01 TW TW101136271A patent/TW201332999A/zh unknown
- 2012-10-01 AR ARP120103660A patent/AR088091A1/es unknown
-
2014
- 2014-03-30 IL IL231814A patent/IL231814A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014003796A (es) | 2015-01-16 |
| AR088091A1 (es) | 2014-05-07 |
| EP2751099A1 (fr) | 2014-07-09 |
| KR20140084112A (ko) | 2014-07-04 |
| AU2012315611A1 (en) | 2014-04-17 |
| CA2850564A1 (fr) | 2013-04-04 |
| TW201332999A (zh) | 2013-08-16 |
| EP2751099B1 (fr) | 2017-06-14 |
| US8846686B2 (en) | 2014-09-30 |
| AU2012315611A8 (en) | 2014-05-08 |
| IL231814A0 (en) | 2014-05-28 |
| CN103958507A (zh) | 2014-07-30 |
| US20130089625A1 (en) | 2013-04-11 |
| WO2013049722A1 (fr) | 2013-04-04 |
| JP2014528419A (ja) | 2014-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014KN00943A (fr) | ||
| MX2015007101A (es) | Compuestos utiles como inhibidores de cinasa relacionada con ataxia telangiectasia mutada y rad3 (atr). | |
| NZ700580A (en) | Compounds useful as inhibitors of atr kinase and combination therapies thereof | |
| MX2012013081A (es) | Compuestos utiles como inhibidores de cinasa atr. | |
| WO2014143242A8 (fr) | Composés utiles en tant qu'inhibiteurs de la kinase atr | |
| MX2012013082A (es) | Derivados de 2-aminopiridina utiles como iinhibidores de cinasa atr. | |
| WO2011143423A3 (fr) | Composés utilisables en tant qu'inhibiteurs de la kinase atr | |
| WO2011143425A3 (fr) | Composés utilisables en tant qu'inhibiteurs de la kinase atr | |
| MX2011006503A (es) | Derivados de pirazina utiles como inhibidores de la cinasa de atr. | |
| HK1223096A1 (zh) | 用作par-2信號通路抑制劑的咪唑並噠嗪 | |
| EP2940017A3 (fr) | Processus de préparation de composés utiles en tant qu'inhibiteurs de kinase d'ATR | |
| MX2011004953A (es) | Compuestos utiles como inhibidores de cinasa atr. | |
| EA201500182A1 (ru) | 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ | |
| MX370390B (es) | Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados. | |
| EA201270480A1 (ru) | Новые соединения | |
| WO2012162254A8 (fr) | Inhibiteurs de l'activité lrrk2 kinase | |
| WO2014194245A3 (fr) | Inhibiteurs de cdk8 et leurs utilisations | |
| EA201300250A1 (ru) | Оксадиазольные ингибиторы продуцирования лейкотриена | |
| MX336051B (es) | Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa. | |
| WO2012048129A3 (fr) | Inhibiteurs de kinase de type polo | |
| IN2014CN03854A (fr) |